Literature DB >> 6133033

Methylmalonic acidaemia due to mutase apoenzyme defect: responsive to vitamin B12 in intact fibroblasts but not in vivo.

R Baumgartner, O Giardini, A Cantani, G Sabetta, M Castro.   

Abstract

Congenital methylmalonic acidaemia (MMA-aemia) was diagnosed in an 8-month-old girl who presented with severe metabolic acidosis, hypoglycaemia and hyperglycinaemia. Vomiting, failure to thrive and apathy first appeared when breast feeding was replaced by a cows' milk formula at the age of 3 months. The patient, unresponsive to OH-Cbl therapy, was successfully treated with dietary protein restriction and with Shohl's solution. Aged 4 years 9 months, she is in good health. Studies in cultured fibroblasts revealed a defect of the MMA-CoA mutase apoenzyme. Mutase activity in cell extracts was barely detectable both with and without added coenzyme (Ado-Cbl). Addition of OH-Cbl to the culture medium improved overall propionate metabolism in intact fibroblasts but had no effect on mutase activity in cell extracts. These observations point to the presence of a very labile mutant enzyme, suggesting that the patient reported here may be suffering from yet another variant of MMA-aemia.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6133033     DOI: 10.1007/bf01800166

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  15 in total

1.  Inherited deficiencies of human methylmalonyl CaA mutase activity: reduced affinity of mutant apoenzyme for adenosylcobalamin.

Authors:  H F Willard; L E Rosenberg
Journal:  Biochem Biophys Res Commun       Date:  1977-10-10       Impact factor: 3.575

2.  A new variant of methylmalonic acidemia-defective coenzyme-apoenzyme binding in cultured fibroblasts.

Authors:  G Morrow; B Revsin; R Clark; J Lebowitz; D T Whelan
Journal:  Clin Chim Acta       Date:  1978-04-03       Impact factor: 3.786

Review 3.  Genetic and biochemical analysis of human cobalamin mutants in cell culture.

Authors:  W A Fenton; L E Rosenberg
Journal:  Annu Rev Genet       Date:  1978       Impact factor: 16.830

4.  Interactions of methylmalonyl CoA mutase from normal human fibroblasts with adenosylcobalamin and methylmalonyl CoA: evidence for non-equivalent active sites.

Authors:  H F Willard; L E Rosenberg
Journal:  Arch Biochem Biophys       Date:  1980-03       Impact factor: 4.013

5.  An improved radioisotope dilution assay for serum vitamin B12 using hemoglobin-coated charcoal.

Authors:  Y K Liu; L W Sullivan
Journal:  Blood       Date:  1972-03       Impact factor: 22.113

6.  Studies of methylmalonyl coenzyme A carbonylmutase activity in methylmalonic acidemia. I. Correlation of clinical, hepatic, and fibroblast data.

Authors:  G Morrow; M J Mahoney; C Mathews; J Lebowitz
Journal:  Pediatr Res       Date:  1975-08       Impact factor: 3.756

7.  Prevalence of homocystinuria among the mentally retarded: evaluation of a specific screening test.

Authors:  G L Spaeth; G W Barber
Journal:  Pediatrics       Date:  1967-10       Impact factor: 7.124

8.  Effect of 2-methylcitrate on citrate metabolism: implications for the management of patients with propionic acidemia and methylmalonic aciduria.

Authors:  S Cheema-Dhadli; C C Leznoff; M L Halperin
Journal:  Pediatr Res       Date:  1975-12       Impact factor: 3.756

9.  Congenital defect in intracellular cobalamin metabolism resulting in homocystinuria and methylmalonic aciduria. II. Biochemical investigations.

Authors:  E R Baumgartner; H Wick; J C Linnell; G E Gaull; C Bachmann; B Steinmann
Journal:  Helv Paediatr Acta       Date:  1979

10.  Inherited methylmalonyl CoA mutase apoenzyme deficiency in human fibroblasts: evidence for allelic heterogeneity, genetic compounds, and codominant expression.

Authors:  H F Willard; L E Rosenberg
Journal:  J Clin Invest       Date:  1980-03       Impact factor: 14.808

View more
  5 in total

1.  Methylmalonic aciduria with homocystinuria: biochemical studies, treatment, and clinical course of a Cbl-C patient.

Authors:  A Ribes; P Briones; M A Vilaseca; M Lluch; M Rodes; A Maya; J Campistol; P Pascual; T Suormala; R Baumgartner
Journal:  Eur J Pediatr       Date:  1990-03       Impact factor: 3.183

2.  Prediction of outcome in isolated methylmalonic acidurias: combined use of clinical and biochemical parameters.

Authors:  F Hörster; S F Garbade; T Zwickler; H I Aydin; O A Bodamer; A B Burlina; A M Das; J B C De Klerk; C Dionisi-Vici; S Geb; G Gökcay; N Guffon; E M Maier; E Morava; J H Walter; B Schwahn; F A Wijburg; M Lindner; S Grünewald; M R Baumgartner; S Kölker
Journal:  J Inherit Metab Dis       Date:  2009-07-31       Impact factor: 4.982

3.  Genetic testing is necessary for correct diagnosis and treatment in patients with isolated methylmalonic aciduria: a case report.

Authors:  Katarína Brennerová; Martina Škopková; Mária Ostrožlíková; Jana Šaligová; Juraj Staník; Vladimír Bzdúch; Daniela Gašperíková
Journal:  BMC Pediatr       Date:  2021-12-16       Impact factor: 2.125

4.  Diagnostic work-up and management of patients with isolated methylmalonic acidurias in European metabolic centres.

Authors:  T Zwickler; M Lindner; H I Aydin; M R Baumgartner; O A Bodamer; A B Burlina; A M Das; J B C DeKlerk; G Gökcay; S Grünewald; N Guffon; E M Maier; E Morava; S Geb; B Schwahn; J H Walter; U Wendel; F A Wijburg; E Müller; S Kölker; F Hörster
Journal:  J Inherit Metab Dis       Date:  2008-05-27       Impact factor: 4.750

Review 5.  Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia.

Authors:  Matthias R Baumgartner; Friederike Hörster; Carlo Dionisi-Vici; Goknur Haliloglu; Daniela Karall; Kimberly A Chapman; Martina Huemer; Michel Hochuli; Murielle Assoun; Diana Ballhausen; Alberto Burlina; Brian Fowler; Sarah C Grünert; Stephanie Grünewald; Tomas Honzik; Begoña Merinero; Celia Pérez-Cerdá; Sabine Scholl-Bürgi; Flemming Skovby; Frits Wijburg; Anita MacDonald; Diego Martinelli; Jörn Oliver Sass; Vassili Valayannopoulos; Anupam Chakrapani
Journal:  Orphanet J Rare Dis       Date:  2014-09-02       Impact factor: 4.123

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.